International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases.

D'Amico, Ferdinando; Rubin, David T.; Kotze, Paulo Gustavo; Magro, Fernando; Siegmund, Britta; Kobayashi, Taku; Olivera, Pablo A.; Bossuyt, Peter; Pouillon, Lieven; Louis, Edouard; Domènech, Eugeni; Ghosh, Subrata; Danese, Silvio; Peyrin-Biroulet, Laurent

doi:10.1002/ueg2.12069

Article (Scientific journals)

International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases.

D'Amico, Ferdinando; Rubin, David T.; Kotze, Paulo Gustavo et al.

2021 • In United European Gastroenterology Journal, 9 (4), p. 451-460

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/266122

DOI
10.1002/ueg2.12069

PubMed
33961734

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

International consensus on methodological issues in standardization of fecal calprotectin measurement in IBD_UEG_PPE.pdf

Publisher postprint (471.12 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

fecal calprotectin; inflammatory bowel disease; measurement; standardization

Abstract :

[en] BACKGROUND: Fecal calprotectin (FC) is a non-invasive marker of gut inflammation which is frequently used to guide therapeutic decisions in patients with inflammatory bowel diseases (IBD). Each step of FC measurement can influence the results, leading to misinterpretations and potentially impacting the management of IBD patients. To date, there is high heterogeneity between FC measurements and no current method is universally accepted as a standard. AIMS: Our aim was to provide clear position statementsabout the pre-analytical and the analytical phases of FC measurement to homogenize FC levels and to minimize variability and risk of misinterpretation through aninternational consensus. MATERIALS & METHODS: Fourteen physicians with expertise in the field of IBD and FC from 11 countries attended a virtual international consensus meeting on July 17th, 2020. A systematic literature was conducted and the literature evidence was shared and discussedamong the participants. Statements were formulated, discussed, and voted. Statements were considered approved if all participants agreed. RESULTS: Nine statements were formulated and approved. Based on the available evidence, quantitative tests should be preferred for measuring FC. Furthermore, FC measurement, if possible, should always be performed with the same method and factors influencing FC levels should be taken into account when interpreting the results. DISCUSSION: FC has an increasingly important role in the management of patients with IBD. However, large multicenter studies should be conducted to define the reproducibility and to confirm the diagnostic accuracy of the available FC tests. CONCLUSION: FC concentrations guide clinicians' treatment decisions. Our statements have a relevant impact in daily practice and could be applied in clinical trials to standardize FC measurement.

Disciplines :

Gastroenterology & hepatology

Author, co-author :

D'Amico, Ferdinando

Rubin, David T.

Kotze, Paulo Gustavo

Magro, Fernando

Siegmund, Britta

Kobayashi, Taku

Olivera, Pablo A.

Bossuyt, Peter

Pouillon, Lieven

Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie

More authors (4 more)

Language :

English

Title :

International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases.

Publication date :

2021

Journal title :

United European Gastroenterology Journal

ISSN :

2050-6406

eISSN :

2050-6414

Publisher :

SAGE, London, United Kingdom

Volume :

Issue :

Pages :

451-460

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

https://doi.org/10.1002/ueg2.12069

Name of the research project :

Materia Prima

Funders :

Amgen Belgique

Commentary :

Available on ORBi :

since 15 December 2021

Statistics

Number of views

83 (5 by ULiège)

Number of downloads

81 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Torres J, Mehandru S, Colombel J-F, Peyrin-Biroulet L. Crohn's disease. The Lancet. 2017;389:1741–55.
Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel J-F. Ulcerative colitis. The Lancet. 2017;389:1756–70.
Annese V, Daperno M, Rutter MD, Amiot A, Bossuyt P, East J, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis. 2013;7:982–1018.
Motaganahalli S, Beswick L, Con D, van Langenberg DR. Faecal calprotectin delivers on convenience, cost reduction and clinical decision-making in inflammatory bowel disease: a real-world cohort study. Intern Med J. 2019;49:94–100.
Mukewar S, Costedio M, Wu X, Bajaj N, Lopez R, Brzezinski A, et al. Severe adverse outcomes of endoscopic perforations in patients with and without IBD. Inflamm Bowel Dis. 2014;20:2056–66.
Shafer LA, Walker JR, Waldman C, Yang C, Michaud V, Bernstein CN, et al. Factors associated with anxiety about colonoscopy: the preparation, the procedure, and the anticipated findings. Dig Dis Sci. 2018;63:610–8.
Mumolo MG, Bertani L, Ceccarelli L, Laino G, Fluri GD, Albano E, et al. From bench to bedside: fecal calprotectin in inflammatory bowel diseases clinical setting. World J Gastroenterol. 2018;24:3681–94.
D’Amico F, Nancey S, Danese S, Peyrin-Biroulet L. A practical guide for faecal calprotectin measurement: myths and realities. J Crohns Colitis. 2021;15(1):152–61.
D’Amico F, Bonovas S, Danese S, Peyrin-Biroulet L. Review article: faecal calprotectin and histologic remission in ulcerative colitis. Aliment Pharmacol Ther. 2020;51:689–98.
Guardiola J, Lobatón T, Rodríguez-Alonso L, Ruiz-Cerulla A, Arajol C, Loayza C, et al. Fecal level of calprotectin identifies histologic inflammation in patients with ulcerative colitis in clinical and endoscopic remission. Clin Gastroenterol Hepatol. 2014;12:1865–70.
Toyonaga T, Kobayashi T, Nakano M, Saito E, Umeda S, Okabayashi S. Usefulness of fecal calprotectin for the early prediction of short-term outcomes of remission-induction treatments in ulcerative colitis in comparison with two-item patient-reported outcome. PloS One. 2017;12:e0185131.
Cremer A, Ku J, Amininejad L, Bouvry M-R, Brohet F, Liefferinckx C, et al. Variability of faecal calprotectin in inflammatory bowel disease patients: an observational case-control study. J Crohns Colitis. 2019;13:1372–9.
Guardiola J, Lobatón T, Cerrillo E, Ferreiro-Iglesias R, Gisbert JP, Domènech E, et al. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the utility of the determination of faecal calprotectin in inflammatory bowel disease. Gastroenterol Hepatol. 2018;41:514–29.
Anon. Calprotectin information for patients | your test for IBS/IBD. Calprotectin. 2020. https://www.calprotectin.co.uk/about-calprotectin/information-for-patients/. Accessed 21 July 2020.
Naismith GD, Smith LA, Barry SJE, Munro JI, Laird S, Rankin K, et al. A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn's disease. Aliment Pharmacol Ther. 2013;37:613–21.
Lasson A, Stotzer P-O, Öhman L, Isaksson S, Sapnara M, Strid H. The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. J Crohns Colitis. 2015;9:26–32.
Calafat M, Cabré E, Mañosa M, Lobatón T, Marín L, Domènech E. High within-day variability of fecal calprotectin levels in patients with active ulcerative colitis. Inflamm Bowel Dis. 2015;21:1072–6.
Kristensen V, Malmstrøm GH, Skar V, Røseth A, Moum B. Clinical importance of faecal calprotectin variability in inflammatory bowel disease: intra-individual variability and standardisation of sampling procedure. Scand J Gastroenterol. 2016;51:548–55.
Du L, Foshaug R, Huang VW, Kroeker KI, Dieleman LA, Halloran BP, et al. Within-stool and within-day sample variability of fecal calprotectin in patients with inflammatory bowel disease. J Clin Gastroenterol. 2018;52:235–40.
Moum B, Jahnsen J, Bernklev T. Fecal calprotectin variability in Crohnʼs disease. Inflamm Bowel Dis. 2010;16:1091–2.
Whitehead SJ, French J, Brookes MJ, Ford C, Gama R. Between-assay variability of faecal calprotectin enzyme-linked immunosorbent assay kits. Ann Clin Biochem. 2013;50:53–61.
Juricic G, Brencic T, Tesija-Kuna A, Njegovan M, Honovic L. Faecal calprotectin determination: impact of preanalytical sample treatment and stool consistency on within- and between-method variability. Biochem Med (Zagreb). 2019;29:010707.
Pansart C, Roblin X, Paul S. Preanalytical heterogeneity in fecal calprotectin measurement needs to Be considered for tight control. Clin Gastroenterol Hepatol. 2020;18:524–525.
RØseth AG, Fagerhol MK, Aadland E, Schjønsby H. Assessment of the neutrophil dominating protein calprotectin in feces: a methodologic study. Scand J Gastroenterol. 1992;27:793–8.
Padoan A, D’Incà R, Scapellato ML, De Bastiani R, Caccaro R, Mescoli C, et al. Improving IBD diagnosis and monitoring by understanding preanalytical, analytical and biological fecal calprotectin variability. Clin Chem Lab Med. 2018;56:1926–35.
Oyaert M, Van den Bremt S, Boel A, Bossuyt X, Van Hoovels L. Do not forget about pre-analytics in faecal calprotectin measurement! Clin Chim Acta. 2017;473:124–6.
Pelkmans LPJ, de Groot MJM, Curvers J. Analytical performance and clinicopathologic correlation of four fecal calprotectin methods. Am J Clin Pathol. 2019;152:392–8.
Theede K, Holck S, Ibsen P, Ladelund S, Nordgaard-Lassen I, Nielsen AM. Level of fecal calprotectin correlates with endoscopic and histologic inflammation and identifies patients with mucosal healing in ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13:1929–36.e1.
Reinisch W, Panaccione R, Bossuyt P, Baert F, Armuzzi A, Hébuterne X, et al. Association of biomarker cutoffs and endoscopic outcomes in crohn's disease: a post hoc analysis from the CALM study. Inflamm Bowel Dis. 2020;26(10):1562–71.
Waugh N, Cummins E, Royle P, Kandala NB, Shyangdan D, Arasaradnam R. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. Health Technol Assess. 2013;17:xv–xix, 1–211.
Tibble J, Teahon K, Thjodleifsson B, Roseth A, Sigthorsson G, Bridger S. A simple method for assessing intestinal inflammation in Crohn's disease. Gut. 2000;47:506–13.
Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119:15–22.
De Sloovere MMW, De Smet D, Baert FJ, Debrabandere J, Vanpoucke HJM. Analytical and diagnostic performance of two automated fecal calprotectin immunoassays for detection of inflammatory bowel disease. Clin Chem Lab Med. 2017;55:1435–46.
Nilsen T, Sunde K, Hansson L-O, Havelka AM, Larsson A. A novel turbidimetric immunoassay for fecal calprotectin optimized for routine chemistry analyzers. J Clin Lab Anal. 2017;31.
Kraemer A, Bulgakova T, Schukina O, Kharitidis A, Kharitonov A, Korostovtseva E. Automated fecal biomarker profiling - a convenient procedure to support diagnosis for patients with inflammatory bowel diseases. Clin Lab. 2020;66.
Radillo O, Pascolo L, Martelossi S, Dal Bo S, Ventura A. Fecal calprotectin: diagnostic accuracy of the immunochromatographic CalFast assay in a pediatric population. J Clin Lab Anal. 2016;30:500–505.
Kittanakom S, Shajib MS, Garvie K, Turner J, Brooks D, Odeh S. Comparison of fecal calprotectin methods for predicting relapse of pediatric inflammatory bowel disease. Can J Gastroenterol Hepatol. 2017;2017:1450970.
Okuyama Y, Doi Y, Matsuyama N, Uchino M, Yamamoto T. A novel sol particle immunoassay for fecal calprotectin in inflammatory bowel disease patients. Clin Chim Acta. 2016;456:1–6.
Mandic-Havelka A, Nilsen T, Sunde K, Norell M, O Hansson L, Larsson A. Turbidimetric determination of fecal calprotectin using two table top chemistry analyzers: Mindray BS-200E and Cobas® c111. Clin Lab. 2017;63:907–13.
Hiraoka S, Takashima S, Inokuchi T, Nakarai A, Takahara M, Harada K, et al. The novel latex agglutination turbidimetric immunoassay system for simultaneous measurements of calprotectin and hemoglobin in feces. Intest Res. 2019;17:202–9.
Rodriguez A, Yokomizo L, Christofferson M, Barnes D, Khavari N, Park K. Correlation of rapid point-of-care vs send-out fecal calprotectin monitoring in pediatric inflammatory bowel disease. Wjgpt. 2017;8:127–30.
Schulz C, Wex T, von Arnim U, Malfertheiner P. Validation of two calprotectin rapid tests in daily routine. Clin Lab. 2016;62:1249–54.
Bin-Nun A, Booms C, Sabag N, Mevorach R, Algur N, Hammerman C. Rapid fecal calprotectin (FC) analysis: point of care testing for diagnosing early necrotizing enterocolitis. Am J Perinatol. 2015;32:337–42.
Lobatón T, López-García A, Rodríguez-Moranta F, Ruiz A, Rodríguez L, Guardiola J. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. Journal of Crohn's and Colitis. 2013;7:e641–e651.
Kolho K, Turner D, Veereman-Wauters G, Sladek M, de Ridder L, Shaoul R, et al. Rapid test for fecal calprotectin levels in children with Crohn disease. J Pediatr Gastroenterol Nutr. 2012;55:436–9.
Damms A, Bischoff SC. Validation and clinical significance of a new calprotectin rapid test for the diagnosis of gastrointestinal diseases. Int J Colorectal Dis. 2008;23:985–92.
Otten CMT, Kok L, Witteman BJM, Baumgarten R, Kampman E, Moons KGM. Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome. Clin Chem Lab Med. 2008;46:1275–80.
Sydora MJ, Sydora BC, Fedorak RN. Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome. Journal of Crohn's and Colitis. 2012;6:207–14.
Wassell J, Wallage M, Brewer E. Evaluation of the Quantum Blue(R) rapid test for faecal calprotectin. Ann Clin Biochem. 2012;49:55–8.
Fukunaga S, Kuwaki K, Mitsuyama K, Takedatsu H, Yoshioka S, Yamasaki H. Detection of calprotectin in inflammatory bowel disease: fecal and serum levels and immunohistochemical localization. Int J Mol Med. 2018;41:107–18.
D’Amico F, Netter P, Baumann C, Veltin M, Zallot C, Aimone-Gastin I, et al. Setting up a virtual calprotectin clinic in inflammatory bowel diseases: literature review and nancy experience. J Clin Med. 2020;9:2697.
Hejl J, Theede K, Møllgren B, Madsen KV, Heidari A, Steig A, et al. Point of care testing of fecal calprotectin as a substitute for routine laboratory analysis. Practical Laboratory Medicine. 2018;10:10–4.
Elkjaer M, Burisch J, Voxen Hansen V, Deibjerg Kristensen B, Slott Jensen J-K, Munkholm P. A new rapid home test for faecal calprotectin in ulcerative colitis. Aliment Pharmacol Ther. 2010;31:323–330.
Piekkala M, Alfthan H, Merras-Salmio L, Puustinen Wikström A, Heiskanen K, Jaakkola T, et al. Fecal calprotectin test performed at home: a prospective study of pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2018;66:926–31.
Bello C, Roseth A, Guardiola J, Reenaers C, Ruiz-Cerulla A, Van Kemseke C, et al. Usability of a home-based test for the measurement of fecal calprotectin in asymptomatic IBD patients. Dig Liver Dis. 2017;49:991–6.
Vinding KK, Elsberg H, Thorkilgaard T, Belard E, Pedersen N, Elkjaer M. Fecal calprotectin measured by patients at home using smartphones-A new clinical tool in monitoring patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22:336–44.
Heida A, Knol M, Kobold AM, Bootsman J, Dijkstra G, van Rheenen PF. Agreement between home-based measurement of stool calprotectin and ELISA results for monitoring inflammatory bowel disease activity. Clin Gastroenterol Hepatol. 2017;15:1742–9.
Wei S-C, Tung C-C, Weng M-T, Wong J-M. Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring. Intest Res. 2018;16:546–53.
Haisma S-M, Galaurchi A, Almahwzi S, Adekanmi Balogun JA, Muller Kobold AC, van Rheenen PF. Head-to-head comparison of three stool calprotectin tests for home use. PloS One. 2019;14:e0214751.
Colombel J-F, Panaccione R, Bossuyt P, Lukas M, Baert F, Vaňásek T. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2018;390:2779–89.
Colombel J-F, D’haens G, Lee W-J, Petersson J, Panaccione R. Outcomes and strategies to support a treat-to-target approach in inflammatory bowel disease: a systematic review. J Crohns Colitis. 2020;14:254–66.
McCombie A, Walmsley R, Barclay M, Ho C, Langlotz T, Regenbrecht H, et al. A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflamm Bowel Dis. 2020;26:1098–109.
Mirsepasi-Lauridsen HC, Bachmann Holmetoft U, Ingdam Halkjær S, Angeliki Krogfelt K, Munk Petersen A. Comparison of three commercial fecal calprotectin ELISA test kits used in patients with Inflammatory Bowel Disease. Scand J Gastroenterol. 2016;51:211–7.
Labaere D, Smismans A, Van Olmen A, Christiaens P, D’Haens G, Moons V, et al. Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease. United European Gastroenterol J. 2014;2:30–7.
Goll R, Heitmann R, Moe ØK, Carlsen K, Florholmen J. Head to head comparison of two commercial fecal calprotectin kits as predictor of Mayo endoscopic sub-score and mucosal TNF expression in ulcerative colitis. PloS One. 2019;14:e0224895.
Oyaert M, Boel A, Jacobs J, Van den Bremt S, De Sloovere M, Vanpoucke H. Analytical performance and diagnostic accuracy of six different faecal calprotectin assays in inflammatory bowel disease. Clin Chem Lab Med. 2017;55:1564–73.
Carrasco-Labra A, Lytvyn L, Falck-Ytter Y, Surawicz CM, Chey WD. AGA technical review on the evaluation of functional diarrhea and diarrhea-predominant irritable bowel syndrome in adults (IBS-D). Gastroenterology. 2019;157:859–80.
Pezzilli R, Barassi A, Morselli Labate AM, Finazzi S, Fantini L, Gizzi G, et al. Fecal calprotectin levels in patients with colonic polyposis. Dig Dis Sci. 2008;53:47–51.
Tursi A, Brandimarte G, Elisei W, Giorgetti GM, Inchingolo CD, Aiello F. Faecal calprotectin in colonic diverticular disease: a case-control study. Int J Colorectal Dis. 2009;24:49–55.
Tibble J, Sigthorsson G, Foster R, Sherwood R, Fagerhol M, Bjarnason I. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut. 2001;49:402–8.
Vavricka SR, Heinrich H, Buetikofer S, Breitenmoser F, Burri E, Schneider-Yin X, et al. The Vampire Study: significant elevation of faecal calprotectin in healthy volunteers after 300 ml blood ingestion mimicking upper gastrointestinal bleeding. United European Gastroenterol J. 2018;6:1007–14.
Shastri YM, Bergis D, Povse N, Schäfer V, Shastri S, Weindel M, et al. Prospective multicenter study evaluating fecal calprotectin in adult acute bacterial diarrhea. Am J Med. 2008;121:1099–106.
Gundling F, Schmidtler F, Hapfelmeier A, Schulte B, Schmidt T, Pehl C, et al. Fecal calprotectin is a useful screening parameter for hepatic encephalopathy and spontaneous bacterial peritonitis in cirrhosis. Liver Int. 2011;31:1406–15.
Conroy S, Hale MF, Cross SS, Swallow K, Sidhu RH, Sargur R, et al. Unrestricted faecal calprotectin testing performs poorly in the diagnosis of inflammatory bowel disease in patients in primary care. J Clin Pathol. 2018;71:316–22.
Hille A, Rave-Fränk M, Christiansen H, Herrmann MKA, Kertesz T, Hermann RM, et al. Faecal calprotectin and lactoferrin values during irradiation of prostate cancer correlate with chronic radiation proctitis: results of a prospective study. Scand J Gastroenterol. 2009;44:939–46.
Yamamoto T, Shimoyama T, Bamba T, Matsumoto K. Consecutive monitoring of fecal calprotectin and lactoferrin for the early diagnosis and prediction of pouchitis after restorative proctocolectomy for ulcerative colitis. Am J Gastroenterol. 2015;110:881–7.
Fauny M, D’Amico F, Bonovas S, Netter P, Danese S, Loeuille D, et al. Faecal calprotectin for the diagnosis of bowel inflammation in patients with rheumatological diseases: a systematic review. J Crohns Colitis. 2020;14:688–93.
Lundgren D, Eklöf V, Palmqvist R, Hultdin J, Karling P. Proton pump inhibitor use is associated with elevated faecal calprotectin levels. A cross-sectional study on subjects referred for colonoscopy. Scand J Gastroenterol. 2019;54:152–7.
Poullis A, Foster R, Mendall MA, Shreeve D, Wiener K. Proton pump inhibitors are associated with elevation of faecal calprotectin and may affect specificity. Eur J Gastroenterol Hepatol. 2003;15:573–4.author reply 574.
Cohen M. Proton pump inhibitors may cause elevation in faecal calprotectin levels. Br J Gen Pract. 2016;66:350.
Tibble JA, Sigthorsson G, Foster R, Scott D, Fagerhol MK, Roseth A, et al. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut. 1999;45:362–6.
Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, Bjarnason I. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology. 2005;128:1172–8.
Jackson MA, Goodrich JK, Maxan M-E, Freedberg DE, Abrams JA, Poole AC, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016;65:749–56.
Kolho K-L, Alfthan H, Hämäläinen E. Effect of bowel cleansing for colonoscopy on fecal calprotectin levels in pediatric patients. J Pediatr Gastroenterol Nutr. 2012;55:751–3.
Joshi S, Lewis SJ, Creanor S, Ayling RM. Age-related faecal calprotectin, lactoferrin and tumour M2-PK concentrations in healthy volunteers. Ann Clin Biochem. 2010;47:259–63.
Mindemark M, Larsson A. Ruling out IBD: estimation of the possible economic effects of pre-endoscopic screening with F-calprotectin. Clin Biochem. 2012;45:552–5.
Poullis A, Foster R, Shetty A, Fagerhol MK, Mendall MA. Bowel inflammation as measured by fecal calprotectin. Cancer Epidemiol Biomarkers Prev. 2004;13:279–84.
Bouri S, Segal J, Oke S, Gabe S, Hart A. PWE-009 the accuracy of faecal calprotectin measurement from stoma effluent in predicting crohn’s disease activity. Gut. 2018;67. A72–A72.
Kotze LMdS, Nisihara RM, Marion SB, Cavassani MF, Kotze PG. FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms. Arq Gastroenterol. 2015;52:50–4.
Kant P, Fazakerley R, Hull MA. Faecal calprotectin levels before and after weight loss in obese and overweight subjects. Int J Obes. 2013;37:317–9.
Stevens TW, D'Haens GR, Duijvestein M, Bemelman WA, Buskens CJ, Gecse KB. Diagnostic accuracy of faecal calprotectin in patients with active perianal fistulas. United European Gastroenterol J. 2019;7:496–506.
Kammerlander H, Nielsen J, Kjeldsen J, Knudsen T, Gradel KO, Friedman S, et al. Fecal calprotectin during pregnancy in women with moderate-severe inflammatory bowel disease. Inflamm Bowel Dis. 2018;24:839–48.
Kim ES, Tarassishin L, Eisele C, Barre A, Nair N, Rendon A. Longitudinal changes in fecal calprotectin levels among pregnant women with and without inflammatory bowel disease and their babies. Gastroenterology. 2020:S0016-5085(20)35532-3.